ATOS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Atossa Therapeutics Inc (ATOS) is not a strong buy for a beginner, long-term investor at this time. Despite some positive momentum in the stock price and a favorable options sentiment, the company’s financials remain weak, with no revenue and consistent losses. Additionally, the technical indicators are mixed, and there are no strong catalysts or recent news to justify a buy recommendation. Holding off on investing until more clarity on the company's progress or financial improvement is advised.
The MACD is positive and expanding, suggesting bullish momentum. However, RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near resistance levels (R1: 4.51, R2: 4.707), which could limit further upside in the short term.
The company has ongoing breast cancer studies (I-SPY and EVANGELINE) with data updates expected later this year. Analysts maintain a buy rating despite a reduced price target.
The company paused the development of Z-endoxifen for metastatic breast cancer, which could delay potential revenue generation. Financials show no revenue and consistent losses, with a cash runway of only one year.
In Q3 2025, the company reported no revenue, a net loss of $8.69M (improved by 20.22% YoY), and an EPS of -1.01 (improved by 17.44% YoY). Gross margin remains at 0%.
Craig-Hallum lowered the price target from $35 to $10 but maintained a buy rating, citing the company's focus on other breast cancer settings and ongoing studies.
